GeronFRA:GON -1.14%39 Gross Margin % is 96.73% as of Mar. 2026, which is 1% below its 10-year median of 97.90. GuruFocus rates FRA:GON with a GF Score™ of 39/100 and a GF Value™ of €6.03 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 733 Biotechnology companies, Geron ranks better than 94.82% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Geron's Gross Profit for the
three
months ended in Mar. 2026 was €43.4 Mil. Geron's Revenue for the
three
months ended in Mar. 2026 was €44.8 Mil. Therefore, Geron's Gross Margin % for the quarter that ended in Mar. 2026 was 96.73%.
The historical rank and industry rank for Geron's Gross Margin % or its related term are showing as below:
FRA:GON'
s Gross Margin % Range Over the Past 10 Years
Min: 97.33 Med: 97.9 Max: 98.37
Current: 97.33
During the past 13 years, the highestGross Margin % of Geron was 98.37%. The lowest was 97.33%. And the median was 97.90%.
FRA:GON's Gross Margin % is ranked better than 94.82% of 733
companies
in the Biotechnology industry
Industry Median: 60.9
vs FRA:GON: 97.33
Geron had a gross margin of 96.73% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Geron was 0.00% per year.
Geron (FRA:GON) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Geron had a gross margin of 96.73% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Geron Gross Margin % Related Terms
Geron Gross Margin % Historical Data
* Premium members only.
The historical data trend for Geron's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:GON vs SPRY, PHAT, DSGN: Gross Margin % Comparison
For the Biotechnology subindustry, Geron's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Geron Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Geron's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Geron's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Geron (FRA:GON) has a Gross Margin % of 96.73% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Geron and its competitors. This is near median its historical median of 97.90. Over the past decade, Geron's Gross Margin % has ranged from 97.33 to 98.37. According to the industry distribution chart, Geron ranks #38 out of 733 companies in the Biotechnology industry, placing it in the top 5.2%.
Is Geron's Gross Margin % too high?
Geron's current Gross Margin % of 96.73% is near median its 10-year median of 97.90. Over the past 10 years, this metric has ranged from a low of 97.33 to a high of 98.37. The Biotechnology industry median Gross Margin % is 60.90. Geron's value of 96.73% is 58.8% above this industry median. Based on the distribution chart, Geron ranks #38 out of 733 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Geron has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Geron's Gross Margin % compare to SPRY and PHAT?
According to the Biotechnology industry distribution chart, Geron ranks #38 out of 733 companies for Gross Margin %. This places Geron in the top 5% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.90. Geron's value of 96.73% is 58.8% above this benchmark. Historically, Geron's own Gross Margin % has ranged from 97.33 to 98.37 over the past decade. While the company's 10-year median is 97.90 vs. the industry median of 60.90, Geron has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Geron's current Gross Margin % of 96.73% is 58.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Geron and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Geron's current Gross Margin % is 96.73%, which is near median its own 10-year median of 97.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geron stock overvalued right now?
Based on GuruFocus' analysis, Geron (FRA:GON) is currently considered Possible Value Trap. The stock's GF Value™ is €6.03, compared to a current price of €1.13 — trading 81.3% below its estimated fair value. The current Gross Margin % is 96.73%, which is near median its 10-year median of 97.90 and 58.8% above the Biotechnology industry median of 60.90. Geron's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Geron (FRA:GON), the current Gross Margin % is 96.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Geron (FRA:GON) Overvalued in 2026?
Based on GuruFocus' analysis, Geron stock appears to be undervalued.
The current stock price of €1.13 is trading 81.3% below its estimated GF Value™ of €6.03.
GuruFocus considers Geron to be Possible Value Trap.
Key valuation signals for FRA:GON:
Gross Margin %: 96.73% (near median its 10-year median of 97.90)
GF Value™: €6.03 vs. price of €1.13 (81.3% below fair value)
Industry Position: 58.8% above the Biotechnology median (#38 of 733)
No single metric tells the full story. See the FRA:GON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
39GF Score
Get the complete analysis for FRA:GON
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GON has been successfully added to your 
